Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01980056

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

Study WCMC IST/VOS/MDS evaluates the safety and tolerability of escalating doses of vosaroxin in adult patients with pathologically confirmed Myelodysplastic Syndrome, or MDS, (< 20% blasts in bone marrow, peripheral blood, or both) by World Health Organization (WHO) classification with an intermediate 2 (INT-2) or high-risk score (ie, ≥ 1.5) as assessed by the International Scoring System (IPSS) after failure of hypomethylating agent-based therapy. Based on 3 completed studies and xenograft models, Vosaroxin is hypothesized to be safe and will effective in this patient population.

Status: 
- Unknown -
Study Date: 
Tue, 10/01/2013 to Mon, 10/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Vosaroxin Dose level 1: Vosaroxin 50 mg/m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg/m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg/m2 IV on Days 1, 4, 8 and 11 of 28 day cycle Dose level 4: Vosaroxin 72 mg/m2 IV on Days 1, 4, 8 and 11 of 28 day cycle